These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30743190)

  • 1. Does influenza vaccination or RSV prophylaxis impact resource utilization for children after the diagnosis of airway disorders?
    Cheng J; Zhao C; Lee HJ
    Int J Pediatr Otorhinolaryngol; 2019 May; 120():20-24. PubMed ID: 30743190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative impact of influenza and respiratory syncytial virus in young children.
    Bourgeois FT; Valim C; McAdam AJ; Mandl KD
    Pediatrics; 2009 Dec; 124(6):e1072-80. PubMed ID: 19933730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status.
    Matias G; Taylor R; Haguinet F; Schuck-Paim C; Lustig R; Shinde V
    BMC Public Health; 2017 Mar; 17(1):271. PubMed ID: 28320361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children.
    Iwane MK; Edwards KM; Szilagyi PG; Walker FJ; Griffin MR; Weinberg GA; Coulen C; Poehling KA; Shone LP; Balter S; Hall CB; Erdman DD; Wooten K; Schwartz B;
    Pediatrics; 2004 Jun; 113(6):1758-64. PubMed ID: 15173503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The population impact of a large school-based influenza vaccination campaign.
    Grijalva CG; Zhu Y; Simonsen L; Mitchel E; Griffin MR
    PLoS One; 2010 Nov; 5(11):e15097. PubMed ID: 21209872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza-related hospitalization and ED visits in children less than 5 years: 2000-2011.
    Jules A; Grijalva CG; Zhu Y; Talbot HK; Williams JV; Poehling KA; Chaves SS; Edwards KM; Schaffner W; Shay DK; Griffin MR
    Pediatrics; 2015 Jan; 135(1):e66-74. PubMed ID: 25489015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season.
    Fanos V; Scarcella A; Puddu M; Gallini F; Tuminelli F; Bragetti P; Gallina MR; Quartulli L; Benincori N; Citro G; Via LD; Barera G; DI Luzio Paparatti U; Merolla R; Romano GV; Guida G; Silvestri M; Rossi GA
    J Chemother; 2009 Jun; 21(3):302-10. PubMed ID: 19567351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha I; McKoy N
    Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Assessment of Healthcare Utilization 5 Years After Respiratory Syncytial Virus Infection in US Infants.
    Simões EAF; Chirikov V; Botteman M; Kwon Y; Kuznik A
    J Infect Dis; 2020 Mar; 221(8):1256-1270. PubMed ID: 31165865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Influenza Vaccination Administered During Hospitalization.
    Tartof SY; Qian L; Liu IA; Tseng HF; Sy LS; Hechter RC; Lewin BJ; Jacobsen SJ
    Mayo Clin Proc; 2019 Mar; 94(3):397-407. PubMed ID: 30635116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
    Amand C; Tong S; Kieffer A; Kyaw MH
    BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study.
    Szilagyi PG; Fairbrother G; Griffin MR; Hornung RW; Donauer S; Morrow A; Altaye M; Zhu Y; Ambrose S; Edwards KM; Poehling KA; Lofthus G; Holloway M; Finelli L; Iwane M; Staat MA;
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):943-51. PubMed ID: 18838647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease.
    Griffin MR; Coffey CS; Neuzil KM; Mitchel EF; Wright PF; Edwards KM
    Arch Intern Med; 2002 Jun; 162(11):1229-36. PubMed ID: 12038940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes.
    Oh PI; Lanctôt KL; Yoon A; Lee DS; Paes BA; Simmons BS; Parison D; Manzi P;
    Pediatr Infect Dis J; 2002 Jun; 21(6):512-8. PubMed ID: 12182374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.